PNC Financial Services Group’s Protalix BioTherapeutics PLX Stock Holding History

PNC Financial Services Group’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47	Hold	20	–	–	﹤0.01%	5172
2026 Q1	$43	Hold	20	–	–	﹤0.01%	5133
2025 Q4	$36	Sell	20 -15	-43%	-$31	﹤0.01%	5112
2025 Q3	$78	Buy	+35	New	+$57	﹤0.01%	5013
2024 Q3	–	Sell	-1,418	Closed	-$1.66K	–	4885
2024 Q2	$1.66K	Buy	+1,418	New	+$1.68K	﹤0.01%	4301
2024 Q1	–	Sell	-19	Closed	-$34	–	4788
2023 Q4	$34	Buy	+19	New	+$30	﹤0.01%	4585

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PNC Financial Services Group's PLX Position: Q2 2026 in Review

PNC Financial Services Group held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 20 shares worth $47. The position accounts for ﹤0.01% of the portfolio, ranked #5172.

PNC Financial Services Group first reported a position in PLX in Q4 2023 and has held it in 6 quarters since. The position peaked at $1.66K in Q2 2024. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

PNC Financial Services Group held 20 shares of Protalix BioTherapeutics worth $47 as of Q2 2026.
PNC Financial Services Group left its Protalix BioTherapeutics share count unchanged in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #5172 holding.
PNC Financial Services Group first reported a position in Protalix BioTherapeutics in Q4 2023 and has held it in 6 quarters since.
PNC Financial Services Group's Protalix BioTherapeutics position peaked at $1.66K in Q2 2024.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.